BIOL - BIOLASE, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
Foothill Ranch,
United States
Type: Equity
BIOL price evolution
BIOL
| (in millions $) | 1 May 2023 | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6.53 | $4.18 | $9.96 | $19.55 |
| Short term investments | ||||
| Net receivables | $5.16 | $5.84 | $4.85 | $6.08 |
| Inventory | $17.77 | $15.88 | $16.43 | $16.57 |
| Total current assets | $31.96 | $28.96 | $33.88 | $44.27 |
| Long term investments | ||||
| Property, plant & equipment | $6.8 | $6.05 | $5.82 | $3.42 |
| Goodwill & intangible assets | $2.93 | $2.93 | $2.93 | $2.93 |
| Total noncurrent assets | $9.98 | $9.23 | $8.98 | $6.59 |
| Total investments | ||||
| Total assets | $41.94 | $38.19 | $42.87 | $50.85 |
| Current liabilities | ||||
| Accounts payable | $7.54 | $5.79 | $4.97 | $4.96 |
| Deferred revenue | $2.44 | $2.53 | $2.22 | $2.82 |
| Short long term debt | $1.4 | $0.7 | ||
| Total current liabilities | $19 | $17.81 | $13.76 | $13.95 |
| Long term debt | $13.93 | $13.09 | $14.22 | $14.32 |
| Total noncurrent liabilities | $14.79 | $15.49 | $15.24 | $15.29 |
| Total debt | $15.33 | $15.05 | $14.22 | $14.32 |
| Total liabilities | $33.79 | $33.3 | $29.01 | $29.24 |
| Shareholders' equity | ||||
| Retained earnings | -$302.02 | -$296.17 | -$286.31 | -$277.92 |
| Other shareholder equity | -$0.65 | -$0.73 | -$1.04 | -$0.89 |
| Total shareholder equity | $8.16 | $4.89 | $13.86 | $21.61 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.18 | $30.18 | $17.88 | $6.1 |
| Short term investments | ||||
| Net receivables | $5.84 | $4.24 | $3.06 | $8.76 |
| Inventory | $15.88 | $12.93 | $11.16 | $10.99 |
| Total current assets | $28.96 | $49.35 | $35.11 | $27.02 |
| Long term investments | ||||
| Property, plant & equipment | $6.05 | $2.78 | $2.76 | $1.47 |
| Goodwill & intangible assets | $2.93 | $2.93 | $2.93 | $2.93 |
| Total noncurrent assets | $9.23 | $5.93 | $5.92 | $4.83 |
| Total investments | ||||
| Total assets | $38.19 | $55.28 | $41.02 | $31.85 |
| Current liabilities | ||||
| Accounts payable | $5.79 | $3.31 | $2.65 | $5.33 |
| Deferred revenue | $2.53 | $2.59 | $2.28 | $2.6 |
| Short long term debt | $0.7 | $13.47 | ||
| Total current liabilities | $17.81 | $13.84 | $11.22 | $25.78 |
| Long term debt | $13.09 | $15.05 | $17.96 | |
| Total noncurrent liabilities | $15.49 | $16.23 | $19.77 | $1.73 |
| Total debt | $15.05 | $15.05 | $17.96 | $13.47 |
| Total liabilities | $33.3 | $30.08 | $31 | $27.5 |
| Shareholders' equity | ||||
| Retained earnings | -$296.17 | -$267.53 | -$251.38 | -$234.55 |
| Other shareholder equity | -$0.73 | -$0.62 | -$0.39 | -$0.7 |
| Total shareholder equity | $4.89 | $25.21 | $10.03 | $0.38 |
| (in millions $) | 1 May 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14.05 | $12.01 | $12.23 | |
| Cost of revenue | $10.46 | $9.56 | $7.09 | |
| Gross Profit | $3.6 | $2.44 | $5.14 | |
| Operating activities | ||||
| Research & development | $2.09 | $1.98 | $1.65 | |
| Selling, general & administrative | $9.94 | $8.12 | $8.54 | |
| Total operating expenses | $12.02 | $10.1 | $10.2 | |
| Operating income | -$8.43 | -$7.65 | -$5.05 | |
| Income from continuing operations | ||||
| EBIT | -$8.31 | -$7.98 | -$5.16 | |
| Income tax expense | $0.09 | -$0.02 | $0.02 | |
| Interest expense | $1.46 | $0.42 | $0.43 | |
| Net income | ||||
| Net income | -$9.86 | -$8.39 | -$5.61 | |
| Income (for common shares) | -$9.86 | -$8.39 | -$5.61 | |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $48.46 | $39.19 | $22.78 | $37.8 |
| Cost of revenue | $32.55 | $22.66 | $16.61 | $23.51 |
| Gross Profit | $15.91 | $16.53 | $6.17 | $14.29 |
| Operating activities | ||||
| Research & development | $7.26 | $6.05 | $3.69 | $4.76 |
| Selling, general & administrative | $33.98 | $26.6 | $21.01 | $25.14 |
| Total operating expenses | $41.25 | $32.96 | $24.71 | $29.91 |
| Operating income | -$25.34 | -$16.43 | -$18.54 | -$15.62 |
| Income from continuing operations | ||||
| EBIT | -$25.78 | -$13.87 | -$14.34 | -$15.74 |
| Income tax expense | $0.11 | $0.07 | $0.13 | -$0.04 |
| Interest expense | $2.75 | $2.22 | $2.36 | $2.16 |
| Net income | ||||
| Net income | -$28.63 | -$16.16 | -$16.83 | -$17.86 |
| Income (for common shares) | -$28.85 | -$16.16 | -$16.83 | -$17.86 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$5.85 | -$9.86 | -$8.39 | -$5.61 |
| Operating activities | ||||
| Depreciation | $0.15 | $0.13 | $0.12 | $0.13 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.69 | $0.72 | $0.59 | $0.89 |
| Total cash flows from operations | -$5.66 | -$5.58 | -$6.55 | -$6.61 |
| Investing activities | ||||
| Capital expenditures | -$0.59 | -$0.47 | -$2.68 | -$0.27 |
| Investments | ||||
| Total cash flows from investing | -$0.59 | -$0.47 | -$2.68 | -$0.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | -$0.03 | -$0.21 | $5.85 |
| Net borrowings | -$1 | |||
| Total cash flows from financing | $8.52 | -$0.03 | -$0.21 | $4.85 |
| Effect of exchange rate | $0.08 | $0.31 | -$0.15 | -$0.22 |
| Change in cash and equivalents | $2.35 | -$5.78 | -$9.59 | -$2.26 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$28.63 | -$16.16 | -$16.83 | -$17.86 |
| Operating activities | ||||
| Depreciation | $0.5 | $0.4 | $0.5 | $0.98 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.41 | $1.83 | $3.37 | $2.74 |
| Total cash flows from operations | -$26.76 | -$16.71 | -$12.79 | -$12.75 |
| Investing activities | ||||
| Capital expenditures | -$3.73 | -$0.71 | -$0.1 | -$0.21 |
| Investments | ||||
| Total cash flows from investing | -$3.73 | -$0.71 | -$0.1 | -$0.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.6 | $29.98 | $5.68 | $9.18 |
| Net borrowings | -$1 | -$0.03 | $2.31 | $2.37 |
| Total cash flows from financing | $4.6 | $29.95 | $24.35 | $10.72 |
| Effect of exchange rate | -$0.11 | -$0.24 | $0.32 | -$0.02 |
| Change in cash and equivalents | -$25.99 | $12.3 | $11.78 | -$2.25 |
News
|
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's...
Investing.com
12 May 2023
|
|
BIOLASE (BIOL) Scheduled to Post Earnings on Thursday
ETF DAILY NEWS
5 May 2022
|
|
StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)
ETF DAILY NEWS
4 May 2022
|
|
74 Biggest Movers From Yesterday
Benzinga
29 Apr 2022
|
|
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.85%
Investing.com
27 Apr 2022
|
|
Research Analysts’ New Coverage for April 27th (AACG, AAMC, AAME, AAU, ABEO, ACM, ACOR, ACRX, AE,...
ETF DAILY NEWS
27 Apr 2022
|
|
StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)
ETF DAILY NEWS
27 Apr 2022
|
|
Analysts’ New Coverage for April 19th (AACG, AAMC, AAME, AAPL, AAU, ABEO, AC, ACOR, ACRX, ACU)
ETF DAILY NEWS
19 Apr 2022
|
|
Zacks: Analysts Expect BIOLASE, Inc. (NASDAQ:BIOL) to Post -$0.03 Earnings Per Share
ETF DAILY NEWS
16 Apr 2022
|
|
BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com
ETF DAILY NEWS
12 Apr 2022
|
Fundamentals
| Market cap | $2.37M |
|---|---|
| Enterprise value | $11.17M |
| Shares outstanding | 26.33M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.27 |
| Book/Share | 0.33 |
| Cash/Share | 0.25 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 6.81 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.68 |
| Quick ratio | 0.75 |